Loading data for REVB — first visit, this takes a few seconds.
Revelation Biosciences, Inc.
0.99 -0.01 (-1.00%)
0.99 +0.00%
- Ринкова капіталізація
- $3.95M
- Обсяг торгів
- 3.44K
- Наступна дата звітності
- Nov 5, 2026
Revelation Biosciences, Inc. (REVB): ціна акції, аналіз і дані
Внутрішня вартість
Прогноз аналітиків
Прогнози по акціях →Останні результати
| Факт | До прогнозу | Зміна р/р | |
|---|---|---|---|
| Виручка | $0 | n/a | n/a |
| EPS | -$0.87 | -$0.04 | +96.90% |
Показники
- Купівля
- 0.68
- Ринкова капіталізація
- 3.95M
- Виручка (ttm)
- n/a
- Чистий прибуток (ttm)
- -19.2M
- -0.14
- 27.03
- 0.04
- -0.34
- P/B (ttm)
- 0.39
- P/S (ttm)
- n/a
- Дата звіту
- Nov 5, 2026
- Продаж
- 1.29
- Обсяг торгів
- 3,445
- Сер. обсяг (20 дн.)
- 41,020
- Відкриття
- 1.00
- Попереднє закриття
- 1.00
- Діапазон дня
- 0.99 - 1.00
- Діапазон за 52 тижні
- 0.88 - 7.60
- Аналітик
- n/a
- Цільова ціна
- n/a
- Дивіденди
- n/a
- Екс-дивідендна дата
- n/a
Про Revelation Biosciences, Inc.
Профіль →Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.